Prev Arrow Stocks

Tilray Inc. ($TLRY) Stock Forecast: Down 5.2% Today

Morpher AI identified a bearish signal. The stock price may continue to fall based on the momentum of the negative news.

What is Tilray Inc.?

Tilray Brands Inc. (TLRY) operates in the cannabis industry and is recognized for its brands and acquisitions. The stock faced a significant downturn in a negative market session.

Why is Tilray Inc. going down?

TLRY stock is down 5.2% on Mar 5, 2026 15:21

  • The purchase of BrewDog brand and assets may have sparked initial investor interest, but the subsequent stock decline suggests concerns over deal execution or financial impacts.
  • Despite expansions in product lines and partnerships, overall market sentiment and uncertainties about the upcoming earnings report likely contributed to TLRY's bearish movement.
  • Good Supply's introduction of high-THC products could have provided a small boost, but the limited availability and regional exclusivity may not have been enough to counter broader market pressures.
  • TLRY's stock outperformance in the last month despite sector challenges highlights investor scrutiny, particularly with the upcoming earnings report shaping market sentiments.

TLRY Price Chart

TLRY Technical Analysis

TLRY News

Tilray Brands Inc. stock falls Tuesday, underperforms market

Tilray Brands Inc. (TLRY) shares fell 3.16% on Tuesday, closing at $7.36, marking the third consecutive day of losses for the company. This decline occurred during a generally negative trading session for the stock market, with both the NASDAQ Composite and Dow Jones Industrial Average also experiencing drops.

https://www.marketwatch.com/data-news/tilray-brands-inc-stock-falls-tuesday-underperforms-market-7c3d778e-7b5332b112ef?gaa_at=eafs&gaa_n=AWEtsqdSHALrOOvgF9SpwUFBe0tOt4aOVM5amy47eF_7Te6bdV-N5EGhfTF6&gaa_ts=69a7f660&gaa_sig=YDeJftvaKunDYpsoiIXGP4AZ9PE3bsEnVVbnQkM5sJhPl-QrAgU0PAyFHAAFU99PLUKV0SkFxhauztGlXZ4mCA%3D%3D

0 News Article Image Tilray Brands Inc. stock falls Tuesday, underperforms market

Tilray to Acquire BrewDog Brand, IP, UK Brewery and 11 Pubs for £33 Million

Tilray Brands has announced its intention to acquire the BrewDog brand, intellectual property, its UK brewery, and 11 pubs for £33 million. This strategic move expands Tilray's presence in the craft beer and hospitality sectors, integrating BrewDog's established assets into its portfolio. The acquisition aims to leverage BrewDog's brand recognition and operational infrastructure.

https://www.brewbound.com/news/tilray-to-acquire-brewdog-brand-ip-uk-brewery-and-11-pubs-for-33-million/

1 News Article Image Tilray to Acquire BrewDog Brand, IP, UK Brewery and 11 Pubs for £33 Million

Tilray Brands, Inc. (TLRY) Rises as Broader Market Declines: Key Points to Consider

Tilray Brands (TLRY) saw a 2.04% increase in its stock price, closing at $7.99, despite a broader market decline, outperforming its sector over the past month. Investors are awaiting its upcoming earnings report, with analysts projecting a significant improvement in losses and an increase in revenue. The company currently holds a Zacks Rank of #3 (Hold) and operates within an industry facing challenges.

https://www.bitget.com/amp/news/detail/12560605224243

2 Missing News Article Image Tilray Brands, Inc. (TLRY) Rises as Broader Market Declines: Key Points to Consider

Good Supply's new high-THC vapes and pre-rolls hit Canadian shelves

Tilray Brands' cannabis brand Good Supply has launched a new spring lineup across Canada, focusing on high-potency vapes, flower, and expanded pre-roll formats. The collection includes new 1g 510 vape cartridges with 91%-97% THC, new flower packs, and limited-edition pre-rolls, designed to meet the growing consumer demand for high-THC products. While the company saw a modest positive market reaction to the news, some products are limited edition or region-exclusive, with availability varying by province.

https://www.stocktitan.net/news/TLRY/good-supply-cannabis-brand-expands-high-potency-portfolio-with-new-r0g8vx6jvi02.html

3 News Article Image Good Supply's new high-THC vapes and pre-rolls hit Canadian shelves

Tilray Expands Product Line and Strategic Partnerships in Growth Push

Tilray Brands is expanding its product line in Canada with a new collection of high-potency cannabis products under its Good Supply brand, targeting substantial growth in the competitive market. Concurrently, the company has secured a significant multi-year licensing agreement with the Carlsberg Group to produce, market, and distribute several of Carlsberg's beer brands in the United States starting in 2027. These strategic initiatives aim to diversify Tilray's revenue streams and solidify its position as a global consumer packaged goods company, attracting positive investor sentiment.

https://www.ad-hoc-news.de/boerse/news/ueberblick/tilray-expands-product-line-and-strategic-partnerships-in-growth-push/68616517

4 News Article Image Tilray Expands Product Line and Strategic Partnerships in Growth Push

Tilray Inc. Price History

29.00.2026 - TLRY Stock was down 7.2%

  • Tilray's stock plummeted by 3.6% recently due to various reasons:
  • Analyst downgrades and missing earnings per share (EPS) figures in the most recent report raised concerns among investors, leading to a decline in stock value.
  • The stock's movement below its 50-day and 200-day moving averages signifies a pessimistic market sentiment.
  • Despite positive updates about expanding its European medical cannabis platform in Italy, the company encounters obstacles like regulatory challenges, competition from multi-state operators, and high short interest, contributing to its overall underwhelming performance.
  • Although the announcement of the SweetWater 420 Fest by Tilray's branch, SweetWater Brewing Company, was positive for the brand, it did not notably impact the stock's trajectory.
  • Various analysts' price targets and ratings, for instance, Canaccord Genuity Group's hold rating and a price target of C$13.00, depict a cautious outlook on Tilray's stock performance in the near future.
  • Investors keenly observe developments regarding the potential reclassification of U.S. medical cannabis and the company's efficacy in managing losses to evaluate future stock performance amidst previous declines and dilution risks.

13.00.2026 - TLRY Stock was down 5.3%

  • Despite achieving record revenue and moving to a net cash position, Tilray's stock witnessed a notable bearish trend.
  • The market reaction may have been influenced by a substantial EPS miss and deeply negative net margins, sparking investor concerns.
  • Analysts recommending exploring alternative investment options despite increased positions from certain institutional investors might have exacerbated the bearish outlook.
  • Ongoing worries surrounding operating losses, potential shareholder dilution, and the necessity for Tilray to capitalize on emerging market trends to enhance margins and cash flow likely played a role in the stock's bearish performance.

24.01.2026 - TLRY Stock was up 5.3%

  • Despite a new exclusive licensing deal for beer distribution in the U.S. with Carlsberg, Tilray's stock continues to struggle, reflecting ongoing financial difficulties and consistent share price decline.
  • The company's active acquisition strategy and continual cash consumption have led to a decrease in shareholder value, prompting analysts to recommend exploring other investment options.
  • Despite a slight decrease in Tilray's stock value during a bullish market period, investors are eagerly awaiting the upcoming earnings report, hoping for positive growth in both earnings per share and revenue for the quarter.
  • The exclusive U.S. licensing agreement with Carlsberg aims to enhance Tilray's presence in the beverage market but market sentiment remains cautious due to the company's historical performance and limited growth prospects.

22.00.2026 - TLRY Stock was up 5.1%

  • TLRY stock experienced a strong bullish movement recently, possibly due to the launch of SweetWater's new high-ABV brew, Big Trip Double IPA, expanding its product offerings to cater to the craft beer market.
  • The establishment of Tilray Medical Italia to strengthen its presence in Italy's medical cannabis market might have also played a role in the positive sentiment, demonstrating the company's dedication to increasing its international ventures.
  • Despite facing recent share price challenges and analyst downgrades, the company's undervaluation as pointed out by Simply Wall St's analysis could have attracted value investors, contributing to the bullish movement.
  • The bullish momentum in TLRY's stock today is thought to be driven by a combination of product expansion in the craft beer sector, strategic endeavors in the medical cannabis market, and potential value opportunities arising from recent price declines.

19.01.2026 - TLRY Stock was up 5.8%

  • Tilray's stock experienced a strong bullish movement of over 4% following the announcement of the exclusive brewing and licensing agreement with Carlsberg Group.
  • The partnership with Carlsberg is expected to bring immediate scale and revenue to Tilray, driving optimism among investors and leading to the bullish market movement.
  • This strategic move aligns with Tilray's focus on partnering with established brands and maximizing its beverage operations, showcasing a promising future for the company in the competitive beer market.
  • The market's positive reaction reflects investor confidence in Tilray's ability to leverage its operational infrastructure effectively and strengthen its position in the premium European segment of the US beer market.

05.01.2026 - TLRY Stock was down 6.6%

  • The acknowledgment of Tilray Pharma's CC Pharma as a TOP 100 Innovator in Germany underlines the company's dedication to innovation and operational excellence within the pharmaceutical distribution industry.
  • Notwithstanding this positive development, the decrease in Tilray Brands shares could be linked to profit-taking by investors following a recent uptrend or broader market uncertainties impacting the stock price.
  • The forthcoming nationwide promotional campaign in Tilray's U.S. craft beer taprooms might have shifted investor attention away from the pharmaceutical sector, resulting in a temporary decline in the stock price.
  • Investors may be anticipating the upcoming financial update in early April to evaluate the company's overall performance and growth trajectory, possibly influencing the bearish sentiment surrounding the stock today.

28.00.2026 - TLRY Stock was down 5.2%

  • Analyst downgrades and a significant earnings per share (EPS) miss contributed to a 3.6% drop in Tilray Brands' shares, leading to the stock trading below its key moving averages.
  • Despite some institutional investment interest, the company reported a deeply negative net margin and is projected to have a negative EPS for the current year, impacting investor sentiment.
  • The expansion of Tilray's European medical cannabis platform through Italy was seen as a positive move, but investors are still awaiting progress on U.S. medical cannabis reclassification and effective management of losses to mitigate risks.
  • The launch of a new high-ABV beer by SweetWater Brewing Company, a subsidiary of Tilray Brands, did not seem to have a significant impact on the stock's bearish movement today.

16.00.2026 - TLRY Stock was down 5.1%

  • Tilray's shares declined by 1.9% today, staying close to its 50-day moving average and below its 200-day average, indicating a bearish sentiment in the market.
  • The company failed to meet quarterly EPS estimates and revealed negative net margins, resulting in a downgrade to a "strong sell" rating by Zacks Research.
  • Despite achieving record Q2 revenues from international operations, Tilray's stock currently holds a Zacks Rank #5 (Strong Sell) primarily due to concerns about its US market prospects.
  • Analysts have a cautious stance on Tilray's stock, advising investors to consider other investment opportunities in light of the company's financial performance and market outlook.

15.00.2026 - TLRY Stock was up 5.3%

  • Tilray reported record Q2 revenues of $218 million, driven by international operations and distribution, showcasing the company's ability to capture market opportunities.
  • Despite a recent EPS miss and negative net margins, the stock saw an increase as investors may be optimistic about the company's long-term growth prospects.
  • The focus on higher-margin international markets and new THC beverage offerings indicates Tilray's commitment to diversification and sustainable profitability, which could have positively influenced investor sentiment.
  • Analysts suggesting to consider other stocks for better investment opportunities may have created some uncertainty, but the overall market movement reflects confidence in Tilray's strategic direction and potential for future growth.

05.02.2026 - TLRY Stock was down 5.2%

  • The purchase of BrewDog brand and assets may have sparked initial investor interest, but the subsequent stock decline suggests concerns over deal execution or financial impacts.
  • Despite expansions in product lines and partnerships, overall market sentiment and uncertainties about the upcoming earnings report likely contributed to TLRY's bearish movement.
  • Good Supply's introduction of high-THC products could have provided a small boost, but the limited availability and regional exclusivity may not have been enough to counter broader market pressures.
  • TLRY's stock outperformance in the last month despite sector challenges highlights investor scrutiny, particularly with the upcoming earnings report shaping market sentiments.

18.01.2026 - TLRY Stock was up 5.5%

  • An analyst has given TLRY a Hold rating and set a price target of C$13, expressing concerns about the beer market and optimism regarding potential US legislation impact.
  • Despite falling short of Q4 earnings projections and recording a negative net margin, Zacks Research upgraded its rating on TLRY from "strong sell" to "hold."
  • A recent partnership with Smartway Pharmaceuticals to enhance the distribution of medical cannabis products in the UK has been seen as a strategic move that likely boosted investor confidence and contributed to positive stock movement.
  • Institutional investors making changes to their holdings by either increasing or starting new positions in TLRY may have helped drive the stock price upwards.

10.01.2026 - TLRY Stock was up 5.2%

  • Tilray's stock showed a robust 1.6% bullish movement today, disregarding recent downgrades and cautious analyst views.
  • Q2 FY2026 saw the company achieving record net revenue due to growth in international medical cannabis sales and Canadian adult-use cannabis. This demonstrates its ability to navigate market fluctuations.
  • The company's expansion of its U.S. beverage alcohol division and recognition of its German medical distribution subsidiary showcase strategic efforts to diversify revenue sources and bolster presence in key markets.
  • Notwithstanding challenges like missed earnings estimates and negative net margin, Tilray's dual focus on medical cannabis and spirits sectors, along with international expansion, appears to have positively impacted investor sentiment and influenced today's bullish movement.
i
Disclaimer
Morpher is not liable for the content of the AI investment insights. Like most GPT-powered tools, these summaries may contain AI hallucinations and inaccurate information. Morpher is not presenting you with any investment advice. All investments involve risk, and the past performance of a security, industry, sector, market, or financial product does not guarantee future results or returns. Investors are fully responsible for any investment decisions they make. Such decisions should be based solely on an evaluation of their financial circumstances, investment objectives, risk tolerance, and liquidity needs. These summaries do not constitute investment advice.